Date of Publication: 05-Feb-2026
INTELLIGENCE OVERVIEW
The EMA’s list of new human medicines under evaluation (February 2026) offers an early view into the next wave of therapies moving toward EU approval.
This evolving pipeline reflects where the industry is heading – more targeted treatments, advanced biologics, and innovation in areas of high unmet medical need. For pharma leaders, this signals upcoming shifts in regulatory strategy, portfolio planning, and market access readiness.
Tracking medicines at this stage enables companies to anticipate regulatory trends today and prepare for the therapies of tomorrow.